Showing results (3521-3530 of 6,794) with videos related to
Sort By:
Pageof 680
Clinical Therapeutics|October 26, 2006
Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part IIGeorge P Giacoia, Donald R MattisonClinical Therapeutics|October 26, 2006
The newborn drug development initiative workshop: Summary proceedings from the neurology group on neonatal seizuresRobert R Clancy, Clinical Therapeutics|October 26, 2006
Cardiovascular support in preterm infantsJacquelyn R Evans, Billie Lou Short, Krisa Van Meurs, et al.Clinical Therapeutics|October 26, 2006
Criteria supporting the study of drugs in the newbornRobert M Ward, William E Benitz, Daniel K Benjamin, et al.Clinical Therapeutics|October 26, 2006
Adherence to infectious diseases society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohortJasmanda H Wu, David H Howard, John E McGowan, et al.Clinical Therapeutics|October 26, 2006
The relationship between body weight and drug costs: An Italian population-based studyEzio Degli Esposti, Alessandra Sturani, Giorgia Valpiani, et al.Clinical Therapeutics|September 20, 2006
A review of the receptor-binding and pharmacokinetic properties of dopamine agonistsTrond Kvernmo, Sebastian Härtter, Erich BurgerClinical Therapeutics|September 20, 2006
Tigecycline: a glycylcycline antimicrobial agentThien-Ly Doan, Horatio B Fung, Dhara Mehta, et al.Clinical Therapeutics|September 20, 2006
Clinically important drug-disease interactions and their prevalence in older adultsCatherine I Lindblad, Joseph T Hanlon, Cynthia R Gross, et al.Clinical Therapeutics|September 20, 2006
Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patientsRonald F Grossman, Mary E Ambrusz, Alan C Fisher, et al.Pageof 680